Univariate analysis of factors affecting OS in MPN-AP/BP
| Variable . | HR (95% CI) . | P value . |
|---|---|---|
| Age ≥ 65 y | 1.840 (1.271, 2.667) | .001 |
| WBC > 25 × 103/μL | 1.812 (1.267, 2.590) | .001 |
| Platelet > 100 × 103/μL | 0.687 (0.497, 0.947) | .022 |
| Hemoglobin > 10 g/dL vs < 8 g/dL | 0.380 (0.240, 0.603) | < .0001 |
| Hemoglobin 8-10 g/dL vs < 8g/dL | 0.626 (0.436, 0.899) | .011 |
| Peripheral blasts ≥ 20% vs < 10% | 1.414 (0.956, 2.094) | .08 |
| Peripheral blasts 10%-19% vs < 10% | 1.242 (0.826, 1.867) | .30 |
| Marrow blasts ≥ 20% vs <10% | 0.882 (0.456, 1.703) | .71 |
| Marrow blasts 10%-19% vs <10% | 0.805 (0.399, 1.626) | .55 |
| Total bilirubin | 0.896 (0.647, 1.242) | .51 |
| Creatinine | 1.164 (0.903, 1.502) | .24 |
| Splenomegaly | 1.259 (0.908, 1.746) | .17 |
| Driver mutation status | ||
| JAK2 | 0.970 (0.697, 1.351) | .86 |
| CALR | 1.056 (0.690, 1.617) | .80 |
| MPL | 1.848 (1.078, 3.166) | .03 |
| Triple negative | 0.722 (0.436, 1.197) | .21 |
| 2017 ELN risk | ||
| High risk vs intermediate/favorable | 1.859 (1.282, 2.696) | .001 |
| Mutation status | ||
| TP53 | 2.085 (1.456, 2.996) | < .0001 |
| IDH1 | 0.885 (0.433, 1.808) | .74 |
| IDH2 | 0.664 (0.389, 1.134) | .13 |
| ASXL1 | 0.897 (0.616, 1.307) | .57 |
| EZH2 | 1.076 (0.609, 1.901) | .80 |
| SRSF2 | 1.113 (0.742, 1.671) | .60 |
| RUNX1 | 0.774 (0.483, 1.241) | .29 |
| Chronic-phase MPN type | ||
| ET vs other | 1.134 (0.694, 1.853) | .62 |
| PMF vs other | 1.194 (0.737, 1.935) | .47 |
| PV vs other | 1.352 (0.803, 2.278) | .26 |
| Variable . | HR (95% CI) . | P value . |
|---|---|---|
| Age ≥ 65 y | 1.840 (1.271, 2.667) | .001 |
| WBC > 25 × 103/μL | 1.812 (1.267, 2.590) | .001 |
| Platelet > 100 × 103/μL | 0.687 (0.497, 0.947) | .022 |
| Hemoglobin > 10 g/dL vs < 8 g/dL | 0.380 (0.240, 0.603) | < .0001 |
| Hemoglobin 8-10 g/dL vs < 8g/dL | 0.626 (0.436, 0.899) | .011 |
| Peripheral blasts ≥ 20% vs < 10% | 1.414 (0.956, 2.094) | .08 |
| Peripheral blasts 10%-19% vs < 10% | 1.242 (0.826, 1.867) | .30 |
| Marrow blasts ≥ 20% vs <10% | 0.882 (0.456, 1.703) | .71 |
| Marrow blasts 10%-19% vs <10% | 0.805 (0.399, 1.626) | .55 |
| Total bilirubin | 0.896 (0.647, 1.242) | .51 |
| Creatinine | 1.164 (0.903, 1.502) | .24 |
| Splenomegaly | 1.259 (0.908, 1.746) | .17 |
| Driver mutation status | ||
| JAK2 | 0.970 (0.697, 1.351) | .86 |
| CALR | 1.056 (0.690, 1.617) | .80 |
| MPL | 1.848 (1.078, 3.166) | .03 |
| Triple negative | 0.722 (0.436, 1.197) | .21 |
| 2017 ELN risk | ||
| High risk vs intermediate/favorable | 1.859 (1.282, 2.696) | .001 |
| Mutation status | ||
| TP53 | 2.085 (1.456, 2.996) | < .0001 |
| IDH1 | 0.885 (0.433, 1.808) | .74 |
| IDH2 | 0.664 (0.389, 1.134) | .13 |
| ASXL1 | 0.897 (0.616, 1.307) | .57 |
| EZH2 | 1.076 (0.609, 1.901) | .80 |
| SRSF2 | 1.113 (0.742, 1.671) | .60 |
| RUNX1 | 0.774 (0.483, 1.241) | .29 |
| Chronic-phase MPN type | ||
| ET vs other | 1.134 (0.694, 1.853) | .62 |
| PMF vs other | 1.194 (0.737, 1.935) | .47 |
| PV vs other | 1.352 (0.803, 2.278) | .26 |
ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera.